Polythiazide

Summary

Polythiazide (CHEMBL1587) is an approved small molecule (ATC C03AA05); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03AA05
• Indications: 1 condition
• Chemistry: 439.9 Da · C11H13ClF3N3O4S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1587
Name	Polythiazide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4870
ATC	C03AA05
Molecular formula	C11H13ClF3N3O4S3
Molecular weight	439.9
InChIKey	CYLWJCABXYDINA-UHFFFAOYSA-N

SMILES: CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F

IUPAC name: 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide

Also known as: Nephril, NSC-108161, P-2525, Politiazida, Polythiazide, Polythiazide component of minizide, Polythiazide component of renese-r, Renese, POLYTHIAZIDE, polythiazide, SID144206688, SID170465068

Patent coverage: 3,119 distinct patent families (11,867 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,794 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).